39 results
8-K
EX-99.1
HGENQ
Humanigen, Inc
14 Nov 22
Humanigen Reports Third Quarter 2022 Financial Results
4:16pm
periods was largely due to a decrease in expenses, mainly Research and Development (R&D) expense. R&D expense decreased by $41.9 million from $60.8 million … $183.8 million for the nine months ended September 30, 2021 to $62.6 million for the nine months ended September 30, 2022. The decrease in R&D expense
8-K
EX-99.1
HGENQ
Humanigen, Inc
12 Aug 22
Humanigen Reports Second Quarter 2022 Financial Results
4:07pm
to a decrease in expenses, mainly Research and Development (“R&D”) expense. R&D expense decreased $36.6 million from $63.0 million for the three months ended … 30, 2021 to $43.7 million for the six months ended June 30, 2022. The decrease in R&D expense is primarily due to decreased lenzilumab manufacturing
8-K
EX-99.1
HGENQ
Humanigen, Inc
26 Jul 22
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
4:05pm
in other R&D costs, and some reduction in general and administrative expenses through headcount reduction as well as other initiatives.
Key elements … primarily funded by partners and we hope to utilize a similar approach with our other programs, reducing our cash-based R&D expenses. We believe
8-K
EX-99.1
HGENQ
Humanigen, Inc
5 May 22
Humanigen Reports First Quarter 2022 Financial Results
4:05pm
. The decrease in net loss was due to a decrease in total expenses, mainly Research and Development (“R&D”) expense. R&D expense decreased $42.7
8-K
EX-99.1
bn0 b2vx7pgj8aupy
28 Feb 22
Humanigen Reports Year-End 2021 Financial Results
4:01pm
8-K
EX-99.1
au25ldxhx
12 Nov 21
Results of Operations and Financial Condition
4:01pm
8-K
EX-99.1
04zsh0lgh1
12 Aug 21
Humanigen Reports Second Quarter 2021 Financial Results
4:01pm
8-K
EX-99.1
fbp7kj6ur y3q
14 Jul 21
Regulation FD Disclosure
11:58am
8-K
EX-99.1
b3f0jfvr1rlra3xr7l
17 Jun 21
Humanigen 2021 Annual Stockholder Meeting June 17
6:30am
8-K
EX-99.1
954n7
13 May 21
Humanigen Reports First Quarter 2021 Financial Results
4:06pm
8-K
EX-99.1
oum0zh1o
12 Nov 20
Results of Operations and Financial Condition
6:06am
424B3
qzohj8e5phdrj5ah 1qt
5 Aug 20
Prospectus supplement
5:06pm
POS AM
9vp489
23 Mar 20
Prospectus update (post-effective amendment)
5:24pm